Merck Buying Caraway Therapeutics For Up To $610M
Merck, represented by Gibson Dunn & Crutcher LLP, said Tuesday it has agreed to buy Caraway Therapeutics Inc. for a total potential consideration of up to $610 million....To view the full article, register now.
Already a subscriber? Click here to view full article